Novel approach to early detection of doxorubicin cardiotoxicity by gadolinium-enhanced cardiovascular magnetic resonance imaging in an experimental model

James C Lightfoot, Ralph B D'Agostino Jr, Craig A Hamilton, Jennifer Jordan, Frank M Torti, Nancy D Kock, James Jordan, Susan Workman, W Gregory Hundley, James C Lightfoot, Ralph B D'Agostino Jr, Craig A Hamilton, Jennifer Jordan, Frank M Torti, Nancy D Kock, James Jordan, Susan Workman, W Gregory Hundley

Abstract

Background: We sought to determine whether cardiovascular magnetic resonance measures of gadolinium (Gd) signal intensity (SI) within the left ventricular myocardium are associated with future changes in left ventricular ejection fraction (LVEF) after receipt of doxorubicin (DOX).

Methods and results: Forty Sprague-Dawley rats were divided into 3 groups scheduled to receive weekly intravenous doses of normal saline (n = 7), 1.5 mg/kg DOX (n = 19), or 2.5 mg/kg DOX (n = 14). Magnetic resonance determinations of LVEF and myocardial Gd-SI were performed before and at 2, 4, 7, and 10 weeks after DOX initiation. During treatment, animals were euthanized at different time points so that histopathologic assessments of the left ventricular myocardium could be obtained. Within-group analyses were performed to examine time-dependent relations between Gd-SI and primary events (deterioration in LVEF or an unanticipated death). Six of 19 animals receiving 1.5 mg/kg DOX and 10 of 14 animals receiving 2.5 mg/kg DOX experienced a primary event; no normal saline animals experienced a primary event. In animals with a primary event, histopathologic evidence of myocellular vacuolization occurred (P = 0.04), and the Gd-SI was elevated relative to baseline at the time of the event (P < 0.0001) and during the measurement period before the event (P = 0.0001). In all animals (including normal saline) without an event, measures of Gd-SI did not differ from baseline.

Conclusions: After DOX, low serial measures of Gd-SI predict an absence of an LVEF drop or unanticipated death. An increase in Gd-SI after DOX forecasts a subsequent drop in LVEF as well as histopathologic evidence of intracellular vacuolization consistent with DOX cardiotoxicity.

Figures

Figure 1. Left ventricular (LV) myocardial signal…
Figure 1. Left ventricular (LV) myocardial signal intensity
In the top left, a middle LV short axis image obtained 20 minutes after gadolinium contrast. As shown, the LV myocardial cavity is white and the LV myocardium is dark. On this short axis image, a region of interest was identified (top right) bounded by the LV endocardial surface (solid line) and the LV epicardial surface (dotted line). Within this region of interest the x, y, and z coordinates along with the signal intensity for all the boxes were recorded (bottom left). The number of voxels along with their intensity was plotted and the mean voxel intensity was determined (bottom right). This value was then subtracted from the background noise to obtain the mean voxel intensity.
Figure 2. Gadolinium CMR sample points and…
Figure 2. Gadolinium CMR sample points and intervals
Longitudinal study design showing the multiple sample points and intervals for assessing the relationship between signal intensity and left ventricular ejection fraction measures. For animals not experiencing events, the last point in time sampled for the animal served as their final sample point (labeled D on the Figure).
Figure 3. Study Design
Figure 3. Study Design
As shown 7, 19, and 14 animals were initiated into this study in groups receiving normal saline, 1.5 mg/kg/week of doxorubicin, and 2.5 mg/kg/week of doxorubicin, respectively. Upon animal sacrifice, 24 animals had not experienced a primary event and 16 animals experienced a primary event (13 with a drop in LVEF; 3 with sudden death)
Figure 4. Serial histograms and histopathology
Figure 4. Serial histograms and histopathology
On the top portion of the Figure, 4 week histograms of the number of pixels (y-axes) and intensities (x-axes) in individual animals after receipt of saline (top left), doxorubicin without (top middle) and with (top right) an ejection fraction (EF) drop. On the right are 40-power haematoxylin and eosin (H&E) histopatholigic images from the same animals. As shown, mean intensity increased in the animals that dropped their EF corresponding to vacuolization (arrows bottom right H&E).
Figure 5. Prediction of future primary events
Figure 5. Prediction of future primary events
Receiving operator characteristic curves to determine the cutoff point for: (1) the signal intensity (SI) of the point prior to a primary event (Gd-PRIOR to EVENT; dotted line); (2) the change in SI from the 2 examinations prior to the primary event (Gd-INTERMEDIATE; dashed line); and (3) the change in SI from baseline to the point prior to the primary event (Gd-BASELINE to PRIOR EVENT; dash/dot line). As shown, changes in SI early in the study predicted future events.
Figure 6. Myocardial morphology
Figure 6. Myocardial morphology
Bar graph displaying the percentage of animals which developed myocellular necrosis, fibrosis, apoptosis, and vacuolar degeneration. Animals experiencing the primary endpoint of death (n=3) or drop in left ventricular ejection fraction (n=13) exhibited more vacuolization relative to animals that did not experience these primary endpoints.

References

    1. Hortobagyi GN. Treatment of breast cancer. N Eng J Med. 1998;339:974–984.
    1. Leandro J, Dyck J, Poppe D, Shore R, Airhart C, Greenberg M, Gilday D, Smallhorn J, Benson L. Cardiac dysfunction late after cardiotoxic therapy for childhood cancer. Am J Cardiol. 1994;74:1152–6.
    1. Gottdiener JS, Mathisen DJ, Borer JS, Bonow RO, Myers CE, Barr LH, Schwartz DE, Bacharach SL, Green MV, Rosenberg SA. Doxorubicin cardiotoxicity: assessment of late left ventricular dysfunction by radionuclide cineangiography. Ann Intern Med. 1981;94:430–5.
    1. Doyle JJ, Neugut AI, Jacobson JS, Grann VR, Hershman DL. Chemotherapy and cardiotoxicity in older breast cancer patients: A population-based study. J Clin Oncol. 2005;23:8597–605.
    1. DeVita V,T. 4th ed Lippincott; Philadelphia, Pennsylvania: 1993. Cancer Principles and Practice of Oncology.
    1. Kim RJ, Wu E, Rafael A, Chen EL, Parker MA, Simonetti O, Klocke FJ, Bonow RO, Judd RM. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med. 2000;343:1445–53.
    1. Hundley WG, Kizilbash AM, Afridi I, Franco F, Peshock RM, Grayburn PA. Administration of an intravenous perfluorocarbon contrast agent improves echocardiographic determination of left ventricular volumes and ejection fraction: comparison with cine magnetic resonance imaging. J Am Coll Cardiol. 1998;32:1426–32.
    1. Chuang ML, Hibberd MG, Salton CJ, Beaudin RA, Riley MF, Parker RA, Douglas PS, Manning WJ. Importance of imaging method over imaging modality in noninvasive determination of left ventricular volumes and ejection fraction: assessment by two- and three-dimensional echocardiography and magnetic resonance imaging. J Am Coll Cardiol. 2000;35:477–84.
    1. Hundley WG, Li HF, Willard JE, Landau C, Lange RA, Meshack BM, Hillis LD, Peshock RM. Magnetic resonance imaging assessment of the severity of mitral regurgitation. Comparison with invasive techniques. Circulation. 1995;92:1151–8.
    1. Martin ET, Fuisz AR, Pohost GM. Imaging cardiac structure and pump function. Cardiol Clin. 1998;16:135–60.
    1. Gerber BL, Rochitte CE, Bluemke DA, Melin JA, Crosille P, Becker LC, Lima JA. Relation between Gd-DTPA contrast enhancement and regional inotropic response in the periphery and center of myocardial infarction. Circulation. 2001;104:998–1004.
    1. Olson HM, Young DM, Prieur DJ, LeRoy AF, Reagan RL. Electrolyte and morphologic alterations of myocardium in adriamycin-treated rabbits. Am J Pathol. 1974;77:439–54.
    1. Choi KM, Kim RJ, Gubernikoff G, Vargas JD, Parker M, Judd RM. Transmural extent of acute myocardial infarction predicts long-term improvement in contractile function. Circulation. 2001;104:1101–7.
    1. Ferrans VJ. Overview of cardiac pathology in relation to anthracycline cardiotoxicity. Cancer Treat Rep. 1978;62:955–61.
    1. Messroghli DR, Niendorf T, Schulz-Menger J, Dietz R, Friedrich MG. T1 mapping in patients with acute myocardial infarction. J Cardiovasc Magn Reson. 2003;5:353–9.
    1. Thompson RC, Canby RC, Lojeski EW, Ratner AV, Fallon JT, Pohost GM. Adriamycin cardiotoxicity and proton nuclear magnetic resonance relaxation properties. Am Heart J. 1987;113:1444–9.
    1. Cottin Y, Ribuot C, Maupoil V, Godin D, Arnould L, Brunotte F, Rochette L. Early incidence of adriamycin treatment on cardiac parameters in the rat. Can J Physiol Pharmacol. 1994;72:140–5.
    1. Wassmuth R, Lentzsch S, Erdbruegger U, Schulz-Menger J, Doerken B, Dietz R, Friedrich MG. Subclinical cardiotoxic effects of anthracyclines as assessed by magnetic resonance imaging-a pilot study. Am Heart J. 2001;141:1007–13.
    1. Yilmaz S, Atessahin A, Sahna E, Karahan I, Ozer S. Protective effect of lycopene on adriamycin-induced cardiotoxicity and nephrotoxicity. Toxicology. 2006;218:164–71.
    1. Herman EH, Ferrans VJ. Animal models of anthracycline cardiotoxicity: Basic mechanisms and cardioprotective activity. Progress in Pediatric Cardiology. 1998;8:49–58.

Source: PubMed

3
Subscribe